AR and prostate carcinoma: Despite gains from early diagnoses, androgen deprivation therapy (ADT) and androgen receptor (AR) signaling inhibitors (ARSIs), prostate cancer (PC) remains a major killer of men and the low survival of patients with distant metastases remains a major clinical challenge.